Blog
RSS FeedPosted by Michael Wonder on 22 Feb 2022
New PMPRB report shows significant consistency in public drug plan coverage across Canada for drugs subject to "Common Drug Review" process
22 February 2022 - The Patented Medicine Prices Review Board released today the third and final part in the Alignment ...
Posted by Michael Wonder on 21 Feb 2022
Proposed PMPRB regulations requires focused dialogue with all players
16 February 2022 - Canada needs an approach that balances pricing considerations with the need to encourage investment, foster innovation, and ...
Posted by Michael Wonder on 13 Jan 2022
Quebec to impose health tax on unvaccinated Canadians
12 January 2022 - The Canadian province of Quebec will charge a health tax to residents who are not vaccinated ...
Posted by Michael Wonder on 23 Sep 2021
Canada should negotiate a fairer share of drug R&D costs
23 September 2021 - Instead of relying on price regulation, Canada should engage in negotiations about drug pricing. ...
Posted by Michael Wonder on 05 Aug 2021
Canadian agency loses a battle in effort to force a drug maker to lower ‘excessive’ pricing
4 August 2021 - In a withering ruling, a Canadian appeals court overturned a controversial decision issued four years ago ...
Posted by Michael Wonder on 04 Aug 2021
Court topples Canadian ruling that one of world's most expensive drugs is excessively priced
3 August 2021 - Soliris was originally approved to treat two blood disorders affecting about 180 Canadians, with the list price ...
Posted by Michael Wonder on 30 Jun 2021
Canada again delays overhaul to patented medicine pricing system
29 June 2021 - Health Minister Patty Hajdu is delaying the first big overhaul of Canada’s patented medicines pricing system ...
Posted by Michael Wonder on 24 Jun 2021
PMPRB risks harming the health of Canadians by reducing access to new medicines
23 June 2021 - On June 21, Innovative Medicines Canada submitted six recommendations to the federal government as part of the ...
Posted by Michael Wonder on 05 Jun 2021
Put Canadians first by suspending the implementation of harmful drug pricing regulations
4 June 2021 - Innovative Medicines Canada calls on the federal government to suspend the implementation of the Patented Medicines ...
Posted by Michael Wonder on 06 May 2021
Alberta, Canada, begins mandating switches from originator to biosimilar Humira
6 May 2021 - Alberta, Canada becomes the latest province to begin switching patients from originator adalimumab (Humira) to biosimilar ...
Posted by Michael Wonder on 24 Jan 2021
Canada’s drug makers rattle their sabers over a government plan to control medicine spending
21 January 2021 - A majority of pharmaceutical executives in Canada say new regulations designed to cut prescription drug spending ...
Posted by Michael Wonder on 21 Jan 2021
Industry pooling helps maintain affordability of high cost drugs despite significant inflationary pressures
21 January 2021 - In 2019, the Canadian Drug Insurance Pooling Corporation's (CDIPC) high-cost drug sharing framework provided coverage to ...
Posted by Michael Wonder on 09 Jan 2021
Health Canada postpones overhaul of drug pricing for 6 months
8 January 2021 - Changes meant to bring down price of prescription drugs pushed to 1 July 2021. ...
Posted by Michael Wonder on 15 Nov 2020
Drug makers offer Canada 1 billion dollars to scrap some pending pricing rules
16 November 2020 - The pharmaceutical industry has made a last-ditch C$1 billion ($761 million) proposal to the Canadian government ...
Posted by Michael Wonder on 24 Oct 2020
Health Canada releases final version of controversial regulations for controlling drug prices
23 October 2020 - After months of delay, Health Canada has released a final version of new regulations that are ...